2. Alvesco Market Definitions Combi R3F1 Alvesco Market R3 Takeda Takeda Takeda Market Segment 3 Segment 2 Segment Mono R3D1 Other All Products from R3 excluding R3D1 and R3F1 Nebuls MDI + DPI Combined Nebuls MDI + DPI Combined R3D1 MDI R3D1 DPI R3F1 MDI R3F1 DPI R3F1 Nebuls R3D1 Nebuls R3 Other All Products from R3D1 when the second letter of the 3 letter Form Code is ‘H’ All Products from R3D1 when the second letter of the 3 letter Form Code is ‘E’ or ‘C’ All Products from R3F1 when the second letter of the 3 letter Form Code is ‘G’ All Products from R3D1 when the second letter of the 3 letter Form Code is ‘G’ All Products from R3F1 when the second letter of the 3 letter Form Code is ‘H’ All Products from R3F1 when the second letter of the 3 letter Form Code is ‘E’ or ‘C’ All Products from R3 excluding R3D1 and R3F1

4. Calcium Market A12A Total (LOCs + Partners) Takeda Takeda Market Segment 2 Segment LOCs Partners LOCs Takeda Performance All Takeda sales for A12A from all countries excluding UK, France, Germany, Italy and Canada All sales for A12A for Corporations excluding Takeda from all countries excluding UK, France, Germany, Italy and Canada LOCs Competitors Partners Takeda Performance Partners Competitors All Calcium sales for A12A from countries UK, France, Germany, Italy and Canada All sales for A12A for Corporations excluding Takeda from countries UK, France, Germany, Italy and Canada Calcium Market Definitions

6. S Takeda Takeda Market Segment 2 Segment Circadin Market All N5B1 Benzo All Products from N5B1where molecule combination does NOT start with ‘Z’ and excluding melatonin Circadin Product Circadin only Takeda Circadin Austria, Belgium, Denmark, Finland, Greece, Netherlands, Norway, Sweden Note : This market is restricted to the following countries Austria, Belgium, Czech Republic, Denmark, Finland, France, Greece, Germany, Hungary, Ireland Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden, United Kingdom Non Benzo All Products from N5B1 where molecule combination DOES start with ‘Z’ Lundbeck Circadin Czech Republic, France, Germany, Hungary, Ireland, Poland, Portugal Slovakia, Spain, United Kingdom Circadin Market Definitions

8. Daxas Market ATC R3 Market Daxas Market Definition

10. Instanyl Market International Products Actiq, Abstral, Effentora, Instanyl and Pecfent from N2A Market Instanyl Market Definition

12. Takeda Takeda Takeda Takeda Market Segment 4 Segment 3 Segment 2 Segment Matrifen Market N2A Immediate Release Opioids Oral Solid Ordinary N2A NFC A Sustained Release Opioids Oral Liquid Ordinary N2A NFC D Parental Ordinary N2A NFC F Other (Rec. Topic. OTH) N2A Excl NFC A, B, D, E, F, G JWM, JWN Other Molecules / Other Duration Patches Local Product Ionsys and/or NFC JWM and molecule sufentanil NFC JWN Matrifen Market (Fentanyl Patches) N2A Plain Buprenorphine NFC JWN Buprenorphine Patches N2A Plain Buprenorphine NFC JWN Oral Solid & Liquid Retard N2A NFC B, E Transdermal Patches N2A NFC JWM, JWN 3 – 4 Day Duration Patches N2A Plain Excl. Local Product Butrans and Norspan 7 Day Duration Patches Local Product Butrans and Norspan Matrifen Market Definitions

14. Omnaris Market All products from R1A1 Market Omnaris Market Definition

16. A2B2 Others All remaining A2B2 Pantoprazole Market A2B2 Takeda Market Segment PPI All A2B2 combinations of the following molecules: pantoprazole, esomeprazole, omeprazole, rabeprazole, lansoprazole, dexlansoprazole Pantoprazole Market Definitions

18. Osteoporosis Market Takeda Takeda Market Segment 2 Segment PTH Market Osteoporosis Others Preotact Market All International Products Forteo and Preotact All International Product Protelos Preotact Broad Market Osteoporosis Other Sub Al Products from M5B, G3J and H4E (except Forteo, Preotact, Protelos) Note: This market is limited to the following countries – Austria, Czech Republic, Denmark, Finland, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Slovakia, Spain, Sweden and UK Preotact Market Definitions

20. TachoSil Market All Products from B2F and B2G Market TachoSil Market Definition

22. IV Forms Takeda Takeda Market Segment 2 Segment NSAIDS + Coxibs All Products from M1A1 and M1A3 NSAIDS Total Forms Xefo Market Other FormsOral Forms N2B All Products from N2B Coxibs NSAIDS + Coxibs All Products from M1A1 and M1A3 with NFC1 A or B N2B All Products from N2B with NFC1 A or B NSAIDS + Coxibs All Products from M1A1 and M1A3 with NFC1 F or G N2B All Products from N2B with NFC1 F or G NSAIDS + Coxibs All Products from M1A1 and M1A3 excl NFC1 A, B, F or G N2B All Products from N2B excl NFC1 A, B, F or G NSAIDS Coxibs All Products from M1A1 with NFC1 A or B All Products from M1A3 with NFC1 A or B All Products from M1A1All Products from M1A3 All Products from M1A1 with NFC1 F or G All Products from M1A3 with NFC1 F or G All Products from M1A1 excl NFC1 A, B, F or G All Products from M1A3 excl NFC1 A, B, F or G Xefo Market Definitions

24. Combi Where ATC3 = C09D Azilsartan Market C09C and C09D Takeda Market Segment Mono Where ATC3 = C09C Azilsartan Market Definitions

26. Combi Where ATC3 = C09D Candesartan Market C09C and C09D Takeda Market Segment Mono Where ATC3 = C09C Candesartan Market Definitions

28. A2B2 Others All remaining A2B2 Lansoprazole Market A2B2 Takeda Market Segment PPI All A2B2 combinations of the following molecules: pantoprazole, esomeprazole, omeprazole, rabeprazole, lansoprazole, dexlansoprazole Lansoprazole Market Definitions

30. Leuprorelin GnRH Analogues Market All combinations of the following molecules: leuprorelin, goserelin, histrelin, triptorelin, degarelix, buserelin Limited to NFCs starting with F or G and NFC AAZ Market The following Molecule and International Strength combinations are excluded : Buserelin 1.05mg/1ml, Buserelin 1.14mg/1ml, Buserelin 100Y/Dose, Buserelin 150Y/Dose Buserelin 182Y/1ml, Buserelin 1mg /1ml, Goserelin + Bicaltamide VARI STR, Triptorelin 1.88mg/1ml, Triptorelin 100Y, Triptorelin 100Y/1ml, Triptorelin 105Y/1ml and Triptorelin 500Y/1ml Leuprorelin Market Definitions

32. Takeda Takeda Market Segment 2 Segment Pioglitazone Market Where ATC3 = A10H, A10J, A10K, A10L, A10M, A10N, A10S DPP-4 + GLP-1 + TZD Where ATC3 = A10K, A10N, A10S All Other Where ATC3 = A10H, A10J, A10L, A10M Pioglitazone Mono Where ATC4 = A10H0, A10J1, A10K1, A10L0 A10M1, A10N1, A10S0 Pioglitazone Combi Where ATC4 = A10J2, A10K2, A10K3, A10M3 A10N3 The following Molecule and International Strength Combinations are excluded : Astragalus + Glibenclamide + Rehmania + Trichosanthes Combi Str, Thiopropazate 3.5mg, Thiopropazate 1.75mg, Thiopropazate 1mg, Astragalus Membranaceus + Glibenclamide + Rehmania + Trichosanthes Combi Str, Glycyclamide 500mg, Composition Unknown NA INTSTR, Glisolamide 5mg, Phenformin 25mg, Phenformin 50mg, Glibenclamide + Phenformin 5mg +25mg, Glibenclamide + Phenformin 2.5mg+25mg, Glibenclamide + Phenformin 2mg+30mg, Tolbutamide 400mg+125mg, Ascorbic Acid + Cyanocobalamin + Pangamic Acid + Phenformin + Pyridoxine + Riboflavin + Thiamine + Tolbutamide Combi Str, Glibenclamide 2.5mg+500mg, Glibenclamide 2.5mg+400mg, Glibenclamide 2.5mg+12.5mg Pioglitazone Market Definitions